Botox (botulinum toxin type A) prior authorization and patient information
Form and prior authorization requirements for Botox (botulinum toxin type A) across multiple indications describing required documentation and prescribing/dispensing details for Cigna coverage.
No material clinical or coverage changes in this revision.
Coverage Criteria and Form Requirements
Form-driven coverage criteria
Coverage consideration requires that ALL indication-specific documentation questions on the form are answered and supporting medical records are attached when requested.
See form fields for billing and submission requirements
See indication-specific prescriber queries on the form
Form asks number of headache days and hours per day; affirmative checkbox for >=15 days with >=4 hours
Form includes prior-trial questions for essential tremor, urologic conditions, NDO, and hyperhidrosis
Form instructs to attach chart notes, labs, claims records, etc.; missing documentation may lead to denial
The prior authorization form does not list indication-based coverage exclusions on the face of the form. Instead, coverage consideration is driven by completion of the form and submission of the requested clinical details — including vial size, total dose, frequency, injection sites/units, J‑code and ICD‑10 — and any attachment of supporting medical records. Incomplete submissions or missing required fields may delay review or lead to denial if the information needed to determine medical necessity is not provided.
The form does not include explicit statements listing services as not medically necessary. However, it requires that documentation supporting the clinical justification be attached (for example, evidence of significant clinical benefit for migraine prevention). If required documentation or answers to the form’s clinical questions are not provided, the request may be considered not medically necessary and could be denied.
Requested Billing Codes and Clinical Thresholds
| J-code | J-Code field on form (specific code to be provided by prescriber) |
| ICD10 | ICD-10 diagnosis code field on form |
Prior Authorization, Documentation, and Step Therapy
Prior Authorization Required
Complete and submit Cigna's Botox prior authorization form with all required patient and prescriber information, medication vial size, total dose, injection sites and units per site, duration and frequency of therapy, J-Code and ICD-10, and whether this is a new or continuation of therapy. Indicate where medication will be obtained (Accredo specialty pharmacy, prescriber's office stock, retail pharmacy, home health/home infusion, or other) and provide facility/dispensing information and applicable CPT code. Attach all requested medical documentation (chart notes, labs, claims) where indicated on the form. Submit via fax to Accredo (888-302-1028) or through CoverMyMeds/SureScripts/EHR e-prescribe per the form instructions. If urgent review is requested, check the Urgent box and call the plan to expedite.
- Medication requested: indicate Botox vial size (50, 100, or 200 unit) and total dose requested
- List each injection site/muscle and number of units per site (form provides 1–10 entries)
- Provide J‑Code and ICD‑10 diagnosis code
- Specify new therapy vs continuation; if continuation for migraine prevention, attach documentation of significant clinical benefit (e.g., reduction in migraine days)
- Where obtained: Accredo (preferred specialty), prescriber office stock, retail, home health, or other (include details)
- Facility/doctor dispensing: CPT code, facility name, address, tax ID
- Submission options: Fax to Accredo (888-302-1028), e-prescribe to Accredo (NCPDP 4436920), verbal to Accredo (866-759-1557), or submit online at CoverMyMeds/SureScripts in your EHR
Step Therapy / Prior Trials
The prior authorization form asks whether the patient has tried ≥1 other pharmacologic therapies for certain indications. Complete the step-therapy questions and list prior agents and trial durations where required. Failure to document prior trials when required may result in denial.
- Essential tremor: indicate whether patient tried ≥1 other pharmacologic therapy (examples: primidone, propranolol, atenolol, sotalol, alprazolam, gabapentin, topiramate)
- Primary axillary hyperhidrosis: document trial of ≥1 prescription topical agent for ≥4 weeks (examples provided on form) and exclusion of secondary causes
- Palmar/plantar/facial hyperhidrosis: document trial of topical agent for ≥4 weeks when applicable
- Overactive bladder and urinary incontinence indications (adult and pediatric NDO): indicate trial of ≥1 other pharmacologic therapy (examples: beta‑3 agonist or anticholinergic)
Documentation Required to Avoid Denial
Complete all asterisked patient and prescriber fields on the form and attach medical documentation requested for the specific diagnosis (chart notes, test results, claims). For migraine prevention or continuation requests, include documentation showing clinical benefit since initiation (e.g., reduction in monthly migraine days or severe migraine days). Requests missing required documentation or responses to form queries may be denied.
- All asterisked (*) patient and prescriber items must be completed for a valid response
- Attach supporting documentation: chart notes, laboratory tests, claims records, or other clinical information as indicated on the form
- For migraine continuation: evidence of significant clinical benefit (examples noted on form) must be attached or request may be denied
- Attestation and prescriber signature/date required
Condition Definitions Referenced on the Form
Background
Botox (botulinum toxin type A) is requested on this form for a range of conditions across specialties — neurologic movement disorders (e.g., blepharospasm, cervical dystonia, essential tremor, focal dystonias), migraine prevention, spasticity, exocrine disorders such as sialorrhea and hyperhidrosis, ophthalmologic indications, and urologic uses including overactive bladder and neurogenic detrusor overactivity. The form collects indication‑specific clinical details and prior therapy information to support medical necessity determinations and to document dosing (vial size, total dose, injection sites and units) and billing fields (J‑code, ICD‑10).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.